Vimarsana
Biggest News Aggregation in the World

Page 49 - Breakthrough Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Breakthrough Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Breakthrough Therapy Today - Breaking & Trending Today

Psychedelics may soon be available — sort of — to treat vets with PTSD - Vimarsana News

Psychedelics may soon be available — sort of — to treat vets with PTSD

In 2017, the U.S. Food and Drug Administration designated MDMA as a “breakthrough therapy” for treatment of post-traumatic stress disorder.

Source: yahoo.com
Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress - Vimarsana News

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Plan to Submit Application for Accelerated Approval for Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in H1 2024 Expects to Begin Enrollment in Phase 3 Confirmatory...

NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023 - Vimarsana News

NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023

RADNOR, Pa., Nov. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. , a late-stage biopharmaceutical company, today announced that it will release its third quarter 2023 financial results after the...

Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test - Vimarsana News

Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test

Potential world-first patented biomarker for long COVID Evaluating diagnostic companion with Bucillamine for long COVID TORONTO, Nov. 06, 2023 -- Revive Therapeutics Ltd. , a specialty life...

Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low - Vimarsana News

Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low

Planned Subgroup Analysis of RAMP 201 Data Showed Combination Demonstrated Robust Efficacy in Recurrent LGSOC Regardless of Number and Class of Prior Therapies Including After Poor Response to Prior TherapyLate-Breaking Abstract Featured as an Oral Presentation during a Plenary Session at the Annual Global Meeting o...